Efficacy and Safety of Norfloxacin 800 mg Once-Daily versus Norfloxacin 400 mg Twice-Daily in the Treatment of Uncomplicated Urinary Tract Infections in Women: A Double-Blind, Randomized Clinical Trial

References

• Sanders CC, Wise R, Weston D, et al. Selection of mul-tiple antibiotic resistance by quinolones, I3-lactams, and amino-glycosides with special reference to cross-resistance between unrelated drug classes. Antimicrob Agents Chemother 1984; 13: 797–801.
   Google Scholar
• Adhami ZN. The pharmacokinetics and tissue penetra-tion of norfloxacin. J Antimicrob Chemother 1984; 13: 87–92.
   PubMed Web of Science ®Google Scholar
• Hughes PJ, Webb DB, Asscher W. Pharmacokinetics of norfloxacin (MK 366) in patients with impaired kidney func-tion - some preliminary results. J Antimicrob Chemother 1984; 13 ( Suppl B) 55-57.
   Google Scholar
• Stein GE. Review of the bioavailability and pharmacoki-netics of oral norfloxacin. Am J Med 1987; 82 (Suppl 6B): 18-21.
   Google Scholar
• Bailey RR, Peddie BA, Blake E. Norfloxacin for the treatment of uncomplicated urinary tract infections. NZ Med J 1983; 8: 446.
   Google Scholar
• Boerema JBJ, Van Saene HK. Norfloxacin treatment in complicated urinary tract infection. Scand J Infect Dis 1986; Suppl 48: 20-26.
   Google Scholar
• Deamey NB, Vogel R, Vanderburg MJ. Norfloxacin in acute urinary tract infections. Practitioner 1984; 228: 111–117.
   PubMedGoogle Scholar
• Lee C. Norfloxacin: its potential in clinical practice. Am J Med 1987; 82 (suppl 6B): 27-34.
   Google Scholar
• Ramirez-Ronda, Colon I, Saavedra S, et al. Treatment of urinary tract infection with norfloxacin. Analysis of cost. Am J Med 1987; 82 (suppl 6B): 75-78.
   Google Scholar
• Schaeffer AJ. Multiclinic study of norfloxacin for treat-ment of urinary tract infections. Am J Med 1987; 82 (suppl 6B): 53-58.
   Google Scholar
• Hussar DA. Importance of patient compliance in effec-tive antimicrobial therapy. Pediatr Infect Dis J 1987; 6: 971–975.
   PubMed Web of Science ®Google Scholar
• Pullar T. Use of pharmacologic indicator to compare compliance with tablets prescribed once, twice or three times daily. Clin Pharmacol Ther 1988, 44 (59): 540–545.
   PubMedGoogle Scholar
• Swanson BN, Boppana BK, Vlasse PH, et al. Norfloxacin disposition after sequentially increasing oral doses. Antimicrob Agents Chemother 1983; 23: 284–288.
   PubMed Web of Science ®Google Scholar
• Guimaraes M, Pimentel FL, Quintas J, et al. Evaluation of the tolerability of a single daily 800 mg dose of norfloxacin. J Chemother 1993; 5 (suppl 1): 359-360.
   Google Scholar
• Smith JT. The mode of action of 4-quinolones and pos-sible mechanisms of resistance. J Antimicrob Chemother 1986; 18: 21–29.
   PubMed Web of Science ®Google Scholar
• Mascellino MT, Lorenzi A, Bonanni M, et al. Antimicrobial activity of norfloxacin in enteric and urinary tract infections: combined effect of norfloxacin with ami-noglycosides, tetracycline and chloramphenicol. Drugs Exptl Clin Res 1986; 319–323.
   PubMedGoogle Scholar
• Norrby SR, Jonsson M. Antibacterial activity of nor-floxacin. Antimicrob Agents Chemother 1983; 23: 15–18.
   PubMed Web of Science ®Google Scholar
• Pantosti A, Giuliano M, Testore GP, et al. Micro-biological and clinical study on a new chemotherapeutic agent for urinary tract infections: MK-0366. Drugs Exptl Clin Res 1984; : 43-45.
   Google Scholar
• Wise RJ. Norfloxacin - a review of pharmacology and tissue penetration. Antimicrob Chemother 1984; 13 ( Suppl B): 59-64.
   Google Scholar
• Cofsky RD. Recovery of norfloxacin in feces after administration of a single oral dose to human volunteers. Antimicrob Agents Chemother 1984; 26: 110–111.
   PubMed Web of Science ®Google Scholar
• Goldenstein JC. Norfloxacin, a fluoroquinolone antibac-terial agent. Classification, mechanism of action and in vitro activity. Am J Med 1987: 82 (suppl 6B): 3-17.
   Google Scholar
• Shungu DL, Weinberg E, Gadebusch HH. In vitro antibacterial activity of norfloxacin (MK-0366, AM-715) and other agents against gastrointestinal tract pathogens. Antimicrob Agents Chemother 1983; 23: 86–90.
   PubMed Web of Science ®Google Scholar
• De Vevey P, Darioli R, BiIle J, et al. Etude comparative du traitement de l'infection urinaire simple par une dose unique de norfloxacine versus cotrimoxazole. Schweiz Med Wschr 1987; 117: 968–973.
   PubMedGoogle Scholar
• Del Favero A, Mencheti F, Guerciolini NI, et al. Norfloxacin versus pipemidic acid in complicated urinary tract infections due to susceptible pathogens: a comparative clinical trial. Chemioterapia 1986; 5: 88–91.
   PubMedGoogle Scholar
• Giamarellou H, Tsagarakis J, Petrikkos, et al. Norfloxacin versus cotrimoxazole in the treatment of lower uri-nary tract infections. Eur J Clin Microbiol 1983; 2: 266–269.
   Google Scholar
• Landes RR, Ronald AR. Norfloxacin vs trimethoprim sulfamethoxazole. A comparative randomized study for the treatment of urinary tract infections. Proc 13th Int Cong Chemother Vienna. 1983: (Tom 5), 38: 25-30.
   Google Scholar
• Sabbaj J, Hoagland VL, Shih WJ. Multicentric compar-ative study of norfloxacin and trimethoprim-sulfamethoxazole for treatment of urinary tract infections. Antimicrob Agents Chemother 1985; 27: 297–301.
   PubMed Web of Science ®Google Scholar
• Sabbaj J, Hoagland VL, Cook T, et al. Norfloxacin ver-sus co-trimoxazole in the treatment of recurring urinary tract infections in man. Scand J Infect Dis 1986; Suppl 48: 48-53.
   Google Scholar
• Corrado ML, Struble WE, Peter C. Norfloxacin: Review of safety studies. Am J Med 1987; 82 (suppl 6B):22-26.
   Google Scholar
• Wang C, Sabbaj J, Corrado M, et al. Worldwide clinical experience with norfloxacin: Efficacy and safety. Scand J Infect Dis 1986; Suppl 48: 81-89.
   Google Scholar